2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163819
    WIZ degrader 3 2839637-72-6 98%
    WIZ degrader 3 (Compound 29) is a degrader for widely interspaced zinc finger motifs (WIZ), with an AC50 of 6.4 nM. WIZ degrader 3 induces the expression of fetal hemoglobin (HbF), with an EC50 of 45 nM. WIZ degrader 3 can be used for the research of blood disorders, such as sickle cell disease and β- thalassemia.
    WIZ degrader 3
  • HY-163859
    LSD1-IN-33 98%
    LSD1-IN-33 (7d), an orally active LSD1 inhibitor with an IC50 of 4.51 nM, alleviates Ang II-induced NRCFs activation in vitro and reducing pathological myocardial remodeling in TAC-induced cardiac remodeling and heart failure in vivo.
    LSD1-IN-33
  • HY-164004
    Stevaladil 6535-03-1 98%
    Stevaladil is an vasodilator.
    Stevaladil
  • HY-164010
    SUN-1334H free base 607737-00-8 98%
    SUN-1334H free base is an orally active inhibitor for histamine H1 receptor, with an IC50 of 20.3 nM and Ki of 9.7 nM. SUN-1334H free base inhibits histamine-induced contractions of isolated guinea-pig ileum with an IC50 of 0.198 μM. SUN-1334H free base inhibits histamine-induced bronchoconstriction in guinea pigs, histamine-induced skin wheals in beagle dogs, and ovalbumin-induced rhinitis in guinea pigs.
    SUN-1334H free base
  • HY-164183
    Trimethaphan bromide 21035-85-8 98%
    Trimethaphan bromide is a ganglionic blocking agent and can be used for study of hypertension.
    Trimethaphan bromide
  • HY-164648
    Flosatidil 113593-34-3 98%
    Flosatidil (SL 85.1016) is an orally active Calcium Channel antagonist. Flosatidil has antianginal and antihypertensive properties.
    Flosatidil
  • HY-164853
    Kanglexin 2228847-12-7 98%
    Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis.
    Kanglexin
  • HY-165424
    NIR-BG2 3036456-18-2 98%
    NIR-BG2 is a near-infrared fluorescent probe targeting senescence-associated β-galactosidase (SA-β-Gal). NIR-BG2 is activated by SA-β-Gal and undergoes hydrolysis to release electrophilic quinone methide that covalently binds to surrounding proteins for in situ labeling, with a 16-fold enhancement of fluorescence signal at 709 nm . NIR-BG2 is promising for research of vivo imaging of cellular senescence.
    NIR-BG2
  • HY-165425
    KR31173 260554-07-2
    KR31173 is an AT1 antagonist with an IC50 of 3.27  nM. KR31173 can be used as a positron emission tomography (PET) tracer after being labeled with 11C isotope. KR31173 shows promising biodistribution and pharmacological properties in mice. KR31173 selectively binds to organs known to contain a high density of AT1 angiotensin receptors in CD-1 mice.
    KR31173
  • HY-165495
    Pafenolol 75949-61-0 98%
    Pafenolol is a selectively oral-active β1 adrenergic receptor (β1-adrenergic receptor) antagonist that effectively lowers blood pressure. Pharmacokinetic studies in rats indicate that the absorption of Pafenolol is influenced by gastrointestinal contents, with food intake reducing the bioavailability of Pafenolol in rats. Pafenolol can be used in research related to cardiovascular diseases and asthma.
    Pafenolol
  • HY-167091
    (Rac)-Beraprost 88430-50-6 98%
    (Rac)-Beraprost ((Rac)-ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis.
    (Rac)-Beraprost
  • HY-167686
    Variabilin 3187-52-8 98%
    Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg.
    Variabilin
  • HY-167688
    GSK-1562590 1003877-55-1 98%
    GSK-1562590 is a uropeptide-II receptor antagonist with high affinity and selectivity. GSK-1562590 exhibits significant antagonistic activity in multiple bioassays and, in contrast, displays relatively sustained receptor binding times. GSK-1562590 can inhibit human urinary peptide-II-induced aortic contraction in rats in experiments, and its effect can last for at least 24 hours.
    GSK-1562590
  • HY-167741
    Chlorisondamine 69-27-2 98%
    Chlorisondamine is a nicotinic antagonist that acts as a ganglionic blocker and has been utilized to evaluate the neurogenic contributions to blood pressure and sympathetic vasomotor tone in animal models. Chlorisondamine has demonstrated antihypertensive properties, primarily being assessed through its effects on blood pressure, cardiac output, and heart rate in various experimental settings, particularly in mice.
    Chlorisondamine
  • HY-167858
    LK-732 673485-33-1 98%
    LK-732 is a thrombin inhibitor with anti-thrombotic activity.LK-732 has a dose-dependent inhibition of hypercoagulability in the model, with an IC50 of 1.3 mg/kg. LK-732 can be used in cardiovascular and cerebrovascular research.
    LK-732
  • HY-168087
    GSK3335103 1893340-21-0 98%
    GSK3335103 is an orally active, non-peptide αvβ6 integrin inhibitor (pIC50=8). GSK3335103 can be used in the study of pulmonary fibrosis.
    GSK3335103
  • HY-168096
    iNOs-IN-5 98%
    iNOs-IN-5 (Compound BN-4) is an inhibitor for iNOS with an IC50 of 0.1707 μM, and reduces NO levels in LPS (HT-D1056)-induced RAW264.7 cells. iNOs-IN-5 reduces the hypoxic injury stimulated ROS and lactate dehydrogenase expression, and exhibits anti-necrosis and anti-apoptosis efficacy. iNOs-IN-5 exhibits anti-cerebral ischemia and neuroprotective activities in SD rat models. iNOs-IN-5 is blood-brain barrier penetrable.
    iNOs-IN-5
  • HY-168120
    Carvacrol-C4-3-hydroxybenzoic acid 98%
    Carvacrol-C4-3-hydroxybenzoic acid (compund 6) has significant cardioprotective activity and good computational ADMET properties.
    Carvacrol-C4-3-hydroxybenzoic acid
  • HY-168130
    TNF-α/IL-1β-IN-1 98%
    TNF-α/IL-1β-IN-1 (compund 11a) is an anti-inflammatory agent that reduces the expression of TNF-α and IL-1β, inhibits oxidative stress and cardiomyocyte apoptosis, has good activity against septic myocardial injury, and improves myocardial blood supply in vivo.
    TNF-α/IL-1β-IN-1
  • HY-168178
    Hsp110-STAT3 interaction-IN-2 98%
    Hsp110-STAT3 interaction-IN-2 (compound 10b) is a Hsp110-STAT3 interaction disruptor. Hsp110-STAT3 interaction-IN-2 can be used in pulmonary arterial hypertension (PAH) related research.
    Hsp110-STAT3 interaction-IN-2
Cat. No. Product Name / Synonyms Application Reactivity